Video

What to Expect When Going on a PARP Inhibitor for Ovarian Cancer

Chemotherapy and PARP inhibitors may share some side effects, but there are some major differences between the two when it comes to treating ovarian cancer.

PARP inhibitors are different than most other ovarian cancer treatments because they are oral agents administered daily.

However, according to Ursula A. Matulonis, M.D., chief of the Division of Gynecologic Oncology at the Dana-Farber Cancer Institute, there are some unifying side effects between PARP inhibitors and traditional ovarian cancer treatments, such as chemotherapy. These include fatigue and gastrointestinal issues.

While, chemotherapy-induced side effects can be long-lasting, most associated with PARP inhibitors stop after about four to six weeks of treatment, she added.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of two doctors and text.
Image of man.
Image of thumbnail.
Patients can prepare personal overviews to help care teams connect with them as individuals, explained Michelle Kirschner in an interview with CURE.
Enhertu with Perjeta nearly doubled progression-free survival versus standard treatment in metastatic HER2-positive breast cancer, study shows.
Expanding on a New Way to Manage Polycythemia Vera Without Iron Deficiency
Image of woman.
Image of two people.
Image of doctor.
Image of woman.
Related Content